* Regents want faculty to resolve differences over severance policy
   
* Five questions for Alan Nelson
   
* Board of Regents announces 2011 awardees
   
* President's Diversity Award winners announced
   
* Open enrollment under way
   
* Did you know...
   
* People
   
* Letters to the editor
 
 NEWS FROM ACROSS CU
 
  CU-BOULDER
  Journalism programs granted provisional reaccreditation
 
  UCCS
  Softball sculpture to be unveiled Friday
 
  CU DENVER
  School of Public Affairs students gain better understanding of 'Our Courts'
 
  ANSCHUTZ MEDICAL CAMPUS
  School of Pharmacy coordinates disposal of unwanted medicine
 
  CU FOUNDATION
  Jewish history program bolstered by $2 million endowed chair
 
  TECH TRANSFER
  Four CU companies receive commercialization grants from state
 
Download Newsleter in PDF
 

Home
Newsletter Archive
Letters to the Editor
Contact Us

   
   
   
   
   
   
   
   
   
   
   

News from across CU
Tech Transfer

Four CU companies receive commercialization grants from state

Four companies formed around technologies developed at the University of Colorado recently were selected to receive funding from Colorado's Bioscience Discovery Evaluation Grant Program. The company grant program (BDEG-Co), launched in 2007 by the state's Office of Economic Development and International Trade, provides early stage matching "seed" grants to enable the development and commercial validation of promising technologies that are licensed from Colorado research institutions by Colorado-based start-up companies.

CU-based companies receiving funding in this round:

  • 2CTech Corp. – The company's proprietary SeeQ technology, based on research by CU Denver researchers Jeffrey Olson and Naresh Mandava, uses intraocularly delivered photoactive nanoparticles (particles that convert light to electrical energy, similar to a conventional solar cell but on a sub-cellular scale) to advance the treatment of ocular diseases such as retinitis pigmentosa, retinal detachment, diabetic retinopathy and macular degeneration, which lead to diminished sight and eventually blindness.

  • BioAMPS International - Focused on the discovery, development and commercialization of proprietary antimicrobial peptide therapeutics for the treatment of systemic infectious diseases because of drug-resistant bacteria. The company's proprietary technology platform, based on work by CU Denver researcher Robert S. Hodges, utilizes novel designs of D-conformation peptides (a type of peptide with increased half-life inside the body) to create unique drug candidates.

  • Mosaic Biosciences - Advancing a fundamentally new class of synthetic materials to support native tissue regeneration. With its proprietary platform technology based on the work of CU-Boulder researchers Christopher Bowman and Kristi Anseth, Mosaic expects to significantly impact the field of tissue regeneration, including applications in wound healing, bone regeneration, cartilage repair, stem cell therapy, and dermal fillers.

  • Suvica – A drug discovery company that uses a novel screening technology developed by CU-Boulder professor Tin Tin Su, which employs mutant Drosophila (fruit flies) to identify and develop compounds that enhance the efficacy of standard cancer treatments and have the potential for use in combination therapy against cancer.

"We are delighted that these CU licensee companies have received these matching grants," said David N. Allen, CU's Associate VP for Technology Transfer. "They represent technologies coming from CU's Boulder and Anschutz Medical campuses, and highlight opportunities for improving human health through drug and medical device products."

Bookmark - Print - Share

 
Previous Tech Transfer Stories

03/16/2011
Lafayette company licenses CU solar technology

03/02/2011
Chicago company licenses CU-developed software used for efficient energy

02/23/2011
AmideBio licenses CU-developed treatment for Alzheimer's disease

02/09/2011
CU licensee acquired by Alexion Pharma in buyout

02/02/2011
Biopharmaceutical company signs license agreement with CU

01/19/2011
Researchers, business leaders honored at annual awards ceremony

10/27/2010
Boulder firm signs research, licensing agreements with CU for heart study

10/13/2010
Symposium to showcase CU's research enterprise

09/29/2010
Anti-cancer compounds licensed from CU

09/22/2010
Aurora company licenses CU technology for brain disease treatment

09/15/2010
Boulder company to commercialize CU hybrid aircraft propulsion technology

07/14/2010
Aurora company licenses unusual approach to treating inflammatory disease

06/30/2010
Optioned device helps diagnose acid reflux, other esophageal diseases

06/16/2010
Taste Connections licenses CU low-protein meat supplement

05/26/2010
White House turns to CU for input on technology commercialization

05/05/2010
Biotech company expands Alzheimer's disease partnership with CU

04/21/2010
Sanofi Pasteur licenses E. coli vaccine technology

04/07/2010
CU ranked 14th among universities in 'Patent Power'

03/31/2010
CU cardiovascular monitoring technology to be commercialized

03/10/2010
Israel-based company licenses water desalination technology

03/03/2010
Colorado company licenses CU test to assess chronic liver disease

01/20/2010
AgriHouse completes license for CU water management technology

01/13/2010
AmideBio licenses technology from CU

01/06/2009
Business collaboration leads to high ranking for CU-Boulder

12/16/2009
License agreement gives Viral Genetics Inc. right to develop cancer therapies

12/09/2009
Soligenix options CU vaccine technology

12/02/2009
Aurora company licenses CU technology for 3-D heart modeling

09/23/2009
Colorado firm aims to commercialize CU breakthroughs in pain management

09/16/2009
Office reports best year for invention disclosures

09/16/2009
Office invites bioscience faculty to submit grant proposals

09/02/2009
Reading software based on CU technology draws national attention

08/19/2009
CU startup to develop 'biogenerator' for medical devices

08/06/2009
CU startup licenses social networking iPhone app

Click for University Relations Web Site E-mail: newsletter@cu.edu